10-Q

Quarterly Report

EVOKE PHARMA, INC.

0000950170-24-123338

← back to feed

Filed

1 year ago Nov 7, 2024 12:00 AM ET

Period of report

—

On SEC.gov

Filing index ↗

Financials in this filing

Metric	Period	Value
Shares Outstanding	Q3 2024 · Nov 6, 2024	1.49M sh
Cash And Equivalents	Q3 2024 · Sep 30, 2024	$11.34M
Cash And Equivalents	Q3 2024 · Dec 31, 2023	$4.74M
Current Liabilities	Q3 2024 · Sep 30, 2024	$9.77M
Current Liabilities	Q3 2024 · Dec 31, 2023	$9.65M
Total Liabilities	Q3 2024 · Sep 30, 2024	$9.77M
Total Liabilities	Q3 2024 · Dec 31, 2023	$9.65M
Current Assets	Q3 2024 · Sep 30, 2024	$14.04M
Current Assets	Q3 2024 · Dec 31, 2023	$6.83M
Total Assets	Q3 2024 · Sep 30, 2024	$14.15M
Total Assets	Q3 2024 · Dec 31, 2023	$7.07M
Stockholders Equity	Q3 2024 · May 14, 2024	$3.5M
Stockholders Equity	Q3 2024 · Sep 30, 2023	−$873.78K
Stockholders Equity	Q3 2024 · Jun 30, 2023	$538.37K
Stockholders Equity	Q3 2024 · Mar 31, 2023	$2.13M
Stockholders Equity	Q3 2024 · Dec 31, 2022	$4.08M
Shares Diluted restated	Q3 2024 · Sep 30, 2023	278.56K sh
Shares Diluted restated	Q3 2024 · Sep 30, 2023	278.56K sh
Operating Cash Flow	Q3 2024 · Sep 30, 2023	−$3.88M
Eps Diluted restated	Q3 2024 · Sep 30, 2023	−$6.08
Eps Diluted restated	Q3 2024 · Sep 30, 2023	−$20.84
Eps Basic restated	Q3 2024 · Sep 30, 2023	−$6.08
Eps Basic restated	Q3 2024 · Sep 30, 2023	−$20.84
Sga Expense	Q3 2024 · Sep 30, 2023	$3.13M
Sga Expense	Q3 2024 · Sep 30, 2023	$8.75M
Net Income	Q3 2024 · Sep 30, 2023	−$1.69M
Net Income	Q3 2024 · Sep 30, 2023	−$5.8M
Net Income	Q3 2024 · Jun 30, 2023	−$1.87M
Net Income	Q3 2024 · Mar 31, 2023	−$2.24M
Operating Income	Q3 2024 · Sep 30, 2023	−$1.6M
Operating Income	Q3 2024 · Sep 30, 2023	−$5.54M
Revenue	Q3 2024 · Sep 30, 2023	$1.56M
Revenue	Q3 2024 · Sep 30, 2023	$3.5M